Physician profile
Martin A Lyons
NPI 1356640379
$17,421.23
in general payments reported to CMS, 2019-2025
55 companies · $3,389 in 2025
The $3,389 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $882 · 2020: $1,577 · 2021: $2,507 · 2022: $2,523 · 2023: $2,846 · 2024: $3,698 · 2025: $3,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,932.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,541.09 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,499.44 | 2023-2025 | Ingrezza, Ongentys |
| Glaxosmithkline, LLC. | $1,473.27 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,401.11 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,328.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,008.70 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $854.92 | 2019-2025 | Rexulti, Jynarque |
| Lilly USA, LLC | $826.15 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $672.99 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $649.95 | 2021-2025 | |
| Amgen INC. | $620.43 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $528.11 | 2019-2025 | Ofev, Jardiance, Jascayd |
| Astellas Pharma US INC | $416.77 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $394.44 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $352.37 | 2019-2025 | Trintellix |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.